Skip to content

Study · Case report or series · n = 1 · 2026

6 results

Liraglutide Causing Pancreatitis in an Indian Obese Female: A Case Report and Review of the Literature.

Singh J, Dinkar A, Verma R, Patel ML, Patwa AK, Bharti N

Current drug safety8 May 2026

PMID42136236 (opens in a new tab)DOI10.2174/0115748863418018251111133620 (opens in a new tab)PepBankPUB-42136236
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 42-year-old Indian woman with obesity, acute interstitial edematous pancreatitis occurred after one month of liraglutide 0.6 mg/day.

    In plain wordsIn a 42-year-old woman with obesity, pancreatitis occurred after one month of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableAcute interstitial edematous pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.6 mg/day · one monthAs given in this study (human).

    Source sentences

    Summary
    Laboratory investigations revealed significantly elevated serum amylase and lipase, while abdominal ultrasonography and contrast-enhanced CT scan confirmed acute interstitial edematous pancreatitis.
    1 context sentence
    Summary · context
    We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation. She had been using liraglutide 0.6 mg/day for one month for weight management.
  2. 02HumanCase report or seriesSafety outcome

    In a 42-year-old Indian woman with obesity using liraglutide, severe epigastric pain developed.

    In plain wordsIn a 42-year-old woman with obesity using liraglutide, severe stomach pain developed.

    Peptide
    Liraglutide
    Outcome
    Not applicableSevere epigastric pain
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.6 mg/day · one monthAs given in this study (human).

    Source sentences

    Summary
    We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation. She had been using liraglutide 0.6 mg/day for one month for weight management.
  3. 03HumanCase report or seriesSafety outcome

    In a 42-year-old Indian woman with obesity using liraglutide, serum amylase was elevated.

    In plain wordsIn a 42-year-old woman with obesity using liraglutide, serum amylase was elevated.

    Peptide
    Liraglutide
    Outcome
    IncreaseElevated serum amylase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.6 mg/day · one monthAs given in this study (human).

    Source sentences

    Summary
    Laboratory investigations revealed significantly elevated serum amylase and lipase, while abdominal ultrasonography and contrast-enhanced CT scan confirmed acute interstitial edematous pancreatitis.
    2 context sentences
    Summary · context
    We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation.
    Summary · context
    She had been using liraglutide 0.6 mg/day for one month for weight management.
  4. 04HumanCase report or seriesSafety outcome

    In a 42-year-old Indian woman with obesity using liraglutide, vomiting developed.

    In plain wordsIn a 42-year-old woman with obesity using liraglutide, vomiting developed.

    Peptide
    Liraglutide
    Outcome
    Not applicableVomiting
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.6 mg/day · one monthAs given in this study (human).

    Source sentences

    Summary
    We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation. She had been using liraglutide 0.6 mg/day for one month for weight management.
  5. 05HumanCase report or seriesSafety outcome

    In a 42-year-old Indian woman with obesity using liraglutide, serum lipase was elevated.

    In plain wordsIn a 42-year-old woman with obesity using liraglutide, serum lipase was elevated.

    Peptide
    Liraglutide
    Outcome
    IncreaseElevated serum lipase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.6 mg/day · one monthAs given in this study (human).

    Source sentences

    Summary
    Laboratory investigations revealed significantly elevated serum amylase and lipase, while abdominal ultrasonography and contrast-enhanced CT scan confirmed acute interstitial edematous pancreatitis.
    2 context sentences
    Summary · context
    We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation.
    Summary · context
    She had been using liraglutide 0.6 mg/day for one month for weight management.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 06HumanNot a test of Liraglutide aloneCase report or seriesOther

    In one 42-year-old Indian woman with obesity and acute pancreatitis after liraglutide use, discontinuation and supportive care were followed by full clinical recovery within five days.

    In plain wordsAfter liraglutide was stopped and supportive care was given, the woman with obesity recovered within five days.

    Peptide
    Liraglutide
    Outcome
    Not applicableClinical recovery after liraglutide discontinuation and supportive care
    Study

    n = 1

    Outcome group
    Overall treatment effect · Gastrointestinal

    Source sentences

    Summary
    Prompt discontinuation of liraglutide and supportive care resulted in full clinical recovery within five days.
    2 context sentences
    Summary · context
    We, herein, report the case of a 42-year-old Indian female with obesity (BMI 32.5 kg/m²) who developed acute-onset severe epigastric pain and vomiting three days prior to presentation.
    Summary · context
    She had been using liraglutide 0.6 mg/day for one month for weight management.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.